New guidelines and the continuous modification of current policies will be needed in order to establish and maintain an appropriate professional relationship between physicians and pharmaceutical companies.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Medical ethicists have discussed the use of race classification in determining disease prevalence and the response of specific ethnic groups to different medications.
Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.